Regulation of bone remodeling by the central and peripheral nervous system

Abstract

The homeostatic nature of bone remodeling has become a notion further supported lately by the demonstration that neuropeptides and their receptors regulate osteoblast and osteoclast function in vivo. Following initial studies reporting the presence of nerves and nerve-derived products within the bone micro-environment and the expression of receptors for these neuropeptides in bone cells, new experimental and mechanistic evidence based on in vivo murine genetic and pharmacologic models recently demonstrated that inputs from the central and peripheral nervous system feed into the already complex regulatory machinery controlling bone remodeling. The function of a number of "osteo-neuromediators" has been characterized, including norepinephrine and the beta 2-adrenergic receptor, Neuropeptide Y and the Y1 and Y2 receptors, endocannabinoids and the CB1 and CB2 receptors, as well as dopamine, serotonin and their receptors and transporters, Calcitonin gene-related peptide, and neuronal NOS. This new body of evidence suggests that neurons in the central nervous system integrate clues from the internal and external milieux, such as energy homeostasis, glycemia or reproductive signals, with the regulation of bone remodeling. The next major tasks in this new area of bone biology will be to understand, at the molecular level, the mechanisms by which common central neural systems regulate and integrate these major physiological functions, the relative importance of the central and peripheral actions of neuropeptides present in both compartments and their relationship, and how bone cells signal back to central centers, because the definition of a homeostatic function implies the existence of feedback signals. Together, these findings shed a new light on the complexity of the mechanisms regulating bone remodeling and uncovered new potential therapeutic strategies for the design of bone anabolic treatments. This review summarizes the latest advances in this area, focusing on investigations based on in vivo animal studies. KeywordsBone; osteoblast; osteoclast; neuron; sympathetic nervous system; hypothalamus; leptin; neuropeptide; adrenergic receptor; neuropeptide Y; endocannabinoid The central nervous system restrains bone formationIt is the association between body weight and bone density as well as the association between loss of gonadal function and osteoporosis that initially pointed to the putative existence of a common factor regulating body weight, reproduction and bone mass. Based on the knowledge that the adipocyte-derived hormone leptin regulates major physiological functions, including body weight and reproduction, via the hypothalamus and its receptor ObRb, it was

Effects of propranolol on the development of glucocorticoid-induced osteoporosis in male rats

“…Propranolol blocks both b -and b -adrenergic receptors and does not have any intrinsic sympathomimetic activity [18]. Recent data indicate that the sympathetic nervous system takes part in the regulation of bone metabolism [13,19,36]. In murine osteoblasts, only the presence of b -receptors has been reported [36], and the positive effects of b-blockers on the skeletal system in experimental conditions are attributed to b -receptors [18].…”

Aluminum Exposure From Parenteral Nutrition in Preterm Infants: Bone Health at 15-Year Follow-up

“…Indeed, bone remodelling is partly controlled by the central nervous system. In animals, several neuropeptides affect bone formation via the hypothalamus, with signal transmission to bone cells via the sympathetic nervous system 15 . Plausibly, then, the effects observed here might be another facet of early aluminium neurotoxicity rather than reflecting a direct effect on bone.…”

Neuropeptide Y Y1 receptor antagonism increases bone mass in mice

“…Advances in understanding of the molecular and cellular biology of bone remodelling have identified the nervous system as a critical modulator of the complex regulatory machinery controlling bone metabolism [6], uncovering potential new targets for bone remodelling therapy. Neuropeptide Y (NPY) is a recently identified osteo-neuromodulator shown to regulate bone cell function [7] and [8].…”